Janssen Presents Results of Nipocalimab (M281) in P-II Vivacity-MG Study for Adults with Generalized Myasthenia Gravis at AAN2021
Shots:
- The P-II Vivacity-MG study involves assessing the safety- tolerability- efficacy- PK- PD- and immunogenicity of nipocalimab in addition to SoC vs PBO in a ratio (1:1:1:1:1) in 68 patients with gMG
- The 1EPs of the study include safety- tolerability- and efficacy assessed by (MG-ADL) ADL score. The 2EPs includes the efficacy as measured by changes in QMG score and revised MG-QoL15 scale from baseline- PK- and PD activity as measured by effects on total serum IgG concentrations- safety and tolerability
- Nipocalimab is a high affinity- fully human- aglycosylated- effectorless IgG1 anti-FcRn mAb and has been received ODD from US FDA for MG
Ref: PR Newswire | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com